Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14421
Country/Region: Zambia
Year: 2015
Main Partner: Southern Province Medical Office - Zambia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $6,029,280 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $900,000
Care: TB/HIV (HVTB) $700,000
Care: Pediatric Care and Support (PDCS) $360,000
Laboratory Infrastructure (HLAB) $275,000
Strategic Information (HVSI) $200,000
Health Systems Strengthening (OHSS) $285,049
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $269,921
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $509,310
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $570,000
Treatment: Adult Treatment (HTXS) $1,360,000
Treatment: Pediatric Treatment (PDTX) $600,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 972
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 1,761
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 918
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 1,656
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 23,827
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 10,698
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 21,024
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 8,874
HTS_TST By Test Result: Negative 2016 42,314
HTS_TST By Test Result: Negative 2016 20,812
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 46,741
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 22,989
HTS_TST Sum of Aggregated Age/Sex <15 2016 1,890
HTS_TST Sum of Aggregated Age/Sex <15 2016 3,417
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 44,851
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 19,572
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 46,741
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 22,989
HTS_TST Sum of Test Result disaggregates 2016 46,741
HTS_TST Sum of Test Result disaggregates 2016 22,989
HTS_TST_POS By Test Result: Positive 2016 4,427
HTS_TST_POS By Test Result: Positive 2016 2,177
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 305
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 176
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 305
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 176
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 260
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 146
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 45
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 30
PMTCT_ARV Sum of New and Current disaggregates 2016 305
PMTCT_ARV Sum of New and Current disaggregates 2016 176
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 35
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 52
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 87
PMTCT_EID Sum of Infant Age disaggregates 2016 87
PMTCT_STAT By: Known positives at entry 2016 45
PMTCT_STAT By: Known positives at entry 2016 81
PMTCT_STAT By: Number of new positives identified 2016 225
PMTCT_STAT By: Number of new positives identified 2016 189
PMTCT_STAT Number of new ANC and L&D clients 2016 9,928
PMTCT_STAT Number of new ANC and L&D clients 2016 1,867
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 9,928
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 1,867
PMTCT_STAT Sum of Positives Status disaggregates 2016 270
PMTCT_STAT Sum of Positives Status disaggregates 2016 270
PP_PREV Age/sex: 10-14 Female 2016 7,978
PP_PREV Age/sex: 10-14 Female 2016 8,407
PP_PREV Age/sex: 10-14 Male 2016 7,603
PP_PREV Age/sex: 10-14 Male 2016 9,021
PP_PREV Age/sex: 15-19 Female 2016 12,183
PP_PREV Age/sex: 15-19 Female 2016 8,278
PP_PREV Age/sex: 15-19 Male 2016 11,080
PP_PREV Age/sex: 15-19 Male 2016 8,274
PP_PREV Age/sex: 20-24 Female 2016 24,031
PP_PREV Age/sex: 20-24 Female 2016 12,189
PP_PREV Age/sex: 20-24 Male 2016 20,305
PP_PREV Age/sex: 20-24 Male 2016 11,778
PP_PREV Age/sex: 25-49 Female 2016 42,796
PP_PREV Age/sex: 25-49 Female 2016 21,405
PP_PREV Age/sex: 25-49 Male 2016 40,182
PP_PREV Age/sex: 25-49 Male 2016 19,185
PP_PREV Age/sex: 50+ Female 2016 11,426
PP_PREV Age/sex: 50+ Female 2016 7,065
PP_PREV Age/sex: 50+ Male 2016 10,922
PP_PREV Age/sex: 50+ Male 2016 7,560
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 188,506
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 113,162
PP_PREV Sum of Age/Sex disaggregates 2016 188,506
PP_PREV Sum of Age/Sex disaggregates 2016 113,162
PP_PREV Total number of people in the target population 2016 246,743
PP_PREV Total number of people in the target population 2016 229,185
TX_CURR Age/Sex: <1 Female 2016 50
TX_CURR Age/Sex: <1 Female 2016 63
TX_CURR Age/Sex: <1 Male 2016 60
TX_CURR Age/Sex: <1 Male 2016 51
TX_CURR Age/Sex: 1-4 Female 2016 712
TX_CURR Age/Sex: 1-4 Female 2016 345
TX_CURR Age/Sex: 1-4 Male 2016 341
TX_CURR Age/Sex: 1-4 Male 2016 344
TX_CURR Age/Sex: 5-14 Female 2016 1,069
TX_CURR Age/Sex: 5-14 Female 2016 1,069
TX_CURR Age/Sex: 5-14 Male 2016 798
TX_CURR Age/Sex: 5-14 Male 2016 1,246
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 23,619
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 24,301
TX_CURR Sum of age/sex disaggregates 2016 24,301
TX_CURR Sum of Age/Sex disaggregations 2016 23,619
TX_NEW Breastfeeding status 2016 158
TX_NEW By Age/Sex: <1 Female 2016 43
TX_NEW By Age/Sex: <1 Male 2016 22
TX_NEW By Age/Sex: 1-4 Female 2016 43
TX_NEW By Age/Sex: 1-4 Male 2016 33
TX_NEW By Age/Sex: 10-14 Female 2016 164
TX_NEW By Age/Sex: 10-14 Male 2016 114
TX_NEW By Age/Sex: 15-19 Female 2016 353
TX_NEW By Age/Sex: 15-19 Male 2016 273
TX_NEW By Age/Sex: 20-24 Female 2016 686
TX_NEW By Age/Sex: 20-24 Male 2016 502
TX_NEW By Age/Sex: 25-49 Female 2016 1,215
TX_NEW By Age/Sex: 25-49 Male 2016 994
TX_NEW By Age/Sex: 5-9 Female 2016 53
TX_NEW By Age/Sex: 5-9 Male 2016 46
TX_NEW By Age/Sex: 50+ Female 2016 355
TX_NEW By Age/Sex: 50+ Male 2016 267
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 5,163
TX_NEW Pregnancy status 2016 192
TX_NEW Sum of Age/Sex disaggregates 2016 5,163
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 4,018
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 4,018
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 115
VMMC_CIRC By Age: <1 2016 12
VMMC_CIRC By Age: 10-14 2016 606
VMMC_CIRC By Age: 15-19 2016 1,657
VMMC_CIRC By Age: 20-24 2016 2,009
VMMC_CIRC By Age: 50+ 2016 575
VMMC_CIRC By circumcision technique: Surgical VMMC 2016 11,458
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2016 123
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 11,335
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 445
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 10,394
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 619
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 11,458
VMMC_CIRC Sum of age disaggregates 2016 4,859